Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

By A. Aupérin, C. Le Péchoux, E. Rolland, W. Curran, K. Furuse, P. Fournel, J. Belderbos, G. Clamon, H. C. Ulutin, R. Paulus and 8 more. Journal of Clinical Oncology, 2010

1,743 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Surgery

View Paper: https://www.semanticscholar.org/paper/8cf414bcf30789db5383abbcd62328efc3fce15d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Vansteenkiste
2. D. Ruysscher
3. W. Eberhardt
4. E. Lim
5. E. Felip
6. Solange Peters
7. S. Senan

Citations in the corpus

• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, neutral): “Sequential CRT (induction ChT followed by RT), usually given at a dose of 60–66 Gy in 30–33 fractions over 6–7 weeks, was compared to concurrent CRT at comparable doses in several phase III trials and in a meta-analysis [120].”
• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, positive): “Induction chemotherapy followed by radiotherapy (mostly to a dose of 60–66 Gy in 30–33 fractions in 6–7 weeks), so-called sequential chemoradiotherapy, was compared with concurrent chemoradiotherapy to the same dose in many phase III trials and in a meta-analysis [51].”